# Regulatory Pathway Labels Explained: Branded, Generic, Compounded and RUO

Evidence & Research Status

FDA StatusNot FDA-approved for human use

Regulatory StatusResearch Use Only (RUO) — not for human consumption

Last UpdatedAugust 31, 2026

What This Article Covers

When the same molecule appears under five different names at five different prices, the difference is almost never the molecule. It is the regulatory pathway it travelled to reach the buyer…

Primary References [Business Standard](https://www.business-standard.com/amp/companies/news/sun-pharma-south-africa-generic-semaglutide-approval-glp-1-diabetes-drug-126071500190_1.html) [Business Day](https://www.businessday.co.za/news/health/2026-07-24-novo-cuts-semaglutide-price-15-with-ozempic-rival-launch/) [IQVIA](https://www.iqvia.com/locations/emea/blogs/2025/07/off-patent-semaglutide)

Evidence Level reflects the general state of published research for this compound category and is not a claim about the safety, efficacy, or approval status of any product sold on this site. All compounds are offered strictly for research use.

When the same molecule appears under five different names at five different prices, the difference is almost never the molecule. It is the **regulatory pathway** it travelled to reach the buyer. [Semaglutide](https://portaltowellness.net/shop/semaglutide-5mg-vial-research-use-only/) is currently the clearest example available, and the labels attached to it are routinely used interchangeably in consumer coverage when they mean quite different things.

This article defines the five categories, explains what evidence and oversight each one carries, and states plainly where Portal to Wellness sits. It is not pricing advice and not a purchasing recommendation.

## The five labels

### 1. Branded

The original product, developed by the company that ran the clinical trials and holds the marketing authorisation. Ozempic and Wegovy are branded [semaglutide](https://portaltowellness.net/research/semaglutide-research-guide/) . The brand carries the full trial dossier, the approved indication wording, the manufacturing inspection history and the pharmacovigilance obligations that go with an approval.

### 2. Generic

A different manufacturer’s version, approved by a regulator after the originator’s patent protection lapses in that market. A generic is not simply a copy — it must demonstrate bioequivalence and meet the same manufacturing standards, and the regulator reviews it before it may be sold.

Sun Pharma received South African regulatory clearance in July 2026 to manufacture and market a generic [semaglutide](https://portaltowellness.net/shop/semaglutide-5mg-vial-research-use-only/) injection, its second such approval after India. Notably, it is approved there for inadequately controlled type 2 diabetes — not as a generic equivalent of the obesity indication. Same molecule, narrower authorisation.

### 3. Authorised copy

A product made by the originator itself, using the same active ingredient, the same manufacturing process and the same device, but sold under a different name at a lower price. Novo Nordisk launched Extensior in South Africa in July 2026 on exactly this model, registered as that market’s only authorised [semaglutide](https://portaltowellness.net/research/semaglutide-research-guide/) copy and priced roughly 15 percent below Ozempic.

An authorised copy is neither a generic nor a compounded preparation. It is the originator competing with its own brand.

### 4. Compounded

A preparation made by a pharmacy for a specific clinical circumstance, under the rules that govern compounding in that jurisdiction. Compounded preparations are not reviewed or approved by the FDA as generics are, and the FDA has stated plainly that compounded medicines do not undergo the same premarket assessment for safety, effectiveness and quality as approved products.

### 5. Research use only

This is the category Portal to Wellness supplies, and it is not a member of the four above.

A research-use-only compound is a laboratory material. It is not a medicine. It has no approved indication, it is not dispensed against a prescription, it is not reviewed by a regulator for safety or efficacy in people, and it is not intended for human or veterinary use. It is not a cheaper version of a drug, and it is not a substitute for one.

That distinction is the entire point of this article. A branded product, a generic and an authorised copy differ from one another in who made them and which regulator cleared them. A research-use-only compound differs in kind: it never entered that system at all.

## Why one molecule sits in five categories at once

Patent protection is national, not global. [Semaglutide](https://portaltowellness.net/shop/semaglutide-5mg-vial-research-use-only/) ‘s compound patents lapsed in several large markets during 2026 — Canada in early January, and India, China, Brazil and South Africa around late March. In the United States, patent term extensions are expected to hold protection until roughly December 2031, and in Europe supplementary protection certificates run to around March 2031.

So at this moment [semaglutide](https://portaltowellness.net/research/semaglutide-research-guide/) is simultaneously an exclusive branded product in the US and EU, a genericised molecule in India and South Africa, and the subject of an originator-authorised discount copy in at least one market. Nothing about the substance changed. The legal position around it did, market by market.

This is why “generic [semaglutide](https://portaltowellness.net/shop/semaglutide-5mg-vial-research-use-only/) exists” is true and misleading at the same time. It exists somewhere. Whether it exists lawfully where a given reader lives is a separate question with a different answer.

## What the price differences actually reflect

Early generic entry tends to produce modest discounts rather than dramatic ones. In South Africa the authorised copy launched around 15 percent below the brand, and early reporting put the first generic in a broadly similar range. Prices typically fall further as more approved entrants arrive, not at the moment the first one does.

The general lesson is that a lower price can reflect a different regulatory pathway, a different market, a different approved indication, or simply a different point in a patent lifecycle. It is not by itself evidence of equivalence, and it is not by itself evidence of a problem.

## Questions worth asking about any label

- Which regulator, if any, reviewed this product, and in which country?
- What indication was it actually authorised for — and is that the use being discussed?
- Was it assessed for bioequivalence against the originator, or not assessed at all?
- Who manufactures it, and is that facility subject to inspection?
- Is it a medicine at all, or a laboratory material being described in medical language?

That last question is the one most often skipped, and it is the one that separates the first four categories from the fifth.

## Where Portal to Wellness sits, stated plainly

Portal to Wellness is not a pharmacy. It does not dispense medicines, does not compound, does not hold a marketing authorisation for anything, and does not sell generics or authorised copies. Everything in the catalogue is supplied strictly as a research-use-only laboratory material, and none of it is intended for human or veterinary use.

If a comparison anywhere implies that a research-use-only compound is an alternative route to a prescription medicine, that comparison is wrong regardless of who is making it.

### Continue Your Research

- [What a study of compounded GLP-1 additives found](https://portaltowellness.net/research/glp-1-additives-compounding-study/)
- [HM17321 and the shift toward body-composition endpoints](https://portaltowellness.net/research/hm17321-muscle-preservation-obesity-research/)

**Sources:** [Business Standard](https://www.business-standard.com/amp/companies/news/sun-pharma-south-africa-generic-semaglutide-approval-glp-1-diabetes-drug-126071500190_1.html) on the Sun Pharma SAHPRA approval; [Business Day](https://www.businessday.co.za/news/health/2026-07-24-novo-cuts-semaglutide-price-15-with-ozempic-rival-launch/) on Extensior pricing; [IQVIA](https://www.iqvia.com/locations/emea/blogs/2025/07/off-patent-semaglutide) on off-patent [semaglutide](https://portaltowellness.net/research/semaglutide-research-guide/) timing; FDA guidance on human drug compounding.

*This article describes regulatory categories only. It is not pricing, purchasing, legal or medical advice, and nothing here should be read as a recommendation to obtain any medicine by any particular route. All compounds sold by Portal to Wellness are supplied strictly for laboratory research use only. They are not drugs, foods, cosmetics or medical devices, are not approved by the FDA, and are not intended to diagnose, treat, cure or prevent any disease. Not for human or veterinary use. No therapeutic claims are made or implied.*

---

Source: https://portaltowellness.net/research/regulatory-pathway-labels-explained/
Research use only. Terms: https://portaltowellness.net/research-use-only/